Krystal Biotech, Inc. Comprehensive Income
Krystal Biotech, Inc. (KRYS) reported Comprehensive Income of $52.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-03
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $52.06M, a 33.14% increase year-over-year.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $53.17M, a 46.43% increase year-over-year.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $51.44M, a 17.50% increase year-over-year.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $79.31M, a 170.44% increase year-over-year.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $206.16M, a 133.39% increase from fiscal 2024.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $88.33M, a 618.26% increase from fiscal 2023.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $12.30M.
- Krystal Biotech, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$140.54M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.06M 10-Q · filed 2026-08-03 | $105.23M 10-Q · filed 2026-08-03 | $156.66M derived: sum of 3 quarters · filed 2026-08-03 | $235.97M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $53.17M 10-Q · filed 2026-05-04 | $104.61M derived: sum of 2 quarters · filed 2026-05-04 | $183.92M derived: sum of 3 quarters · filed 2026-05-04 | $223.02M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $51.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $130.74M derived: sum of 2 quarters · filed 2026-02-17 | $169.84M derived: sum of 3 quarters · filed 2026-08-03 | $206.16M 10-K · filed 2026-02-17 |
| 2025-09-30 | $79.31M 10-Q · filed 2025-11-03 | $118.41M derived: sum of 2 quarters · filed 2026-08-03 | $154.72M 10-Q · filed 2025-11-03 | $198.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $39.10M 10-Q · filed 2026-08-03 | $75.41M 10-Q · filed 2026-08-03 | $119.19M derived: sum of 3 quarters · filed 2026-08-03 | $148.52M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $36.31M 10-Q · filed 2026-05-04 | $80.09M derived: sum of 2 quarters · filed 2026-05-04 | $109.42M derived: sum of 3 quarters · filed 2026-05-04 | $124.65M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $43.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $73.10M derived: sum of 2 quarters · filed 2026-02-17 | $88.34M derived: sum of 3 quarters · filed 2026-02-17 | $88.33M 10-K · filed 2026-02-17 |
| 2024-09-30 | $29.33M 10-Q · filed 2025-11-03 | $44.56M derived: sum of 2 quarters · filed 2025-11-03 | $44.55M 10-Q · filed 2025-11-03 | $54.27M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $15.23M 10-Q · filed 2025-08-04 | $15.23M 10-Q · filed 2025-08-04 | $24.94M derived: sum of 3 quarters · filed 2026-02-17 | $105.54M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$5.00K 10-Q · filed 2025-05-06 | $9.71M derived: sum of 2 quarters · filed 2026-02-17 | $90.31M derived: sum of 3 quarters · filed 2026-02-17 | $57.02M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $9.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $90.31M derived: sum of 2 quarters · filed 2026-02-17 | $57.02M derived: sum of 3 quarters · filed 2026-02-17 | $12.30M 10-K · filed 2026-02-17 |
| 2023-09-30 | $80.60M 10-Q · filed 2024-11-04 | $47.31M derived: sum of 2 quarters · filed 2024-11-04 | $2.59M 10-Q · filed 2024-11-04 | -$28.72M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | -$33.29M 10-Q · filed 2024-08-05 | -$78.02M 10-Q · filed 2024-08-05 | -$109.32M derived: sum of 3 quarters · filed 2025-02-19 | -$139.10M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$44.72M 10-Q · filed 2024-05-06 | -$76.03M derived: sum of 2 quarters · filed 2025-02-19 | -$105.81M derived: sum of 3 quarters · filed 2025-02-19 | -$134.26M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$31.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$61.09M derived: sum of 2 quarters · filed 2025-02-19 | -$89.54M derived: sum of 3 quarters · filed 2025-02-19 | -$140.54M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$29.78M 10-Q · filed 2023-11-06 | -$58.24M derived: sum of 2 quarters · filed 2023-11-06 | -$109.23M 10-Q · filed 2023-11-06 | -$131.19M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$28.46M 10-Q · filed 2023-08-07 | -$79.45M 10-Q · filed 2023-08-07 | -$101.41M derived: sum of 3 quarters · filed 2024-02-26 | -$116.99M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$51.00M 10-Q · filed 2023-05-08 | -$72.95M derived: sum of 2 quarters · filed 2024-02-26 | -$88.54M derived: sum of 3 quarters · filed 2024-02-26 | -$104.92M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$21.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$37.54M derived: sum of 2 quarters · filed 2024-02-26 | -$53.92M derived: sum of 3 quarters · filed 2024-02-26 | -$69.74M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$15.58M 10-Q · filed 2022-11-07 | -$31.97M derived: sum of 2 quarters · filed 2022-11-07 | -$47.78M 10-Q · filed 2022-11-07 | -$58.18M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$16.39M 10-Q · filed 2022-08-08 | -$32.20M 10-Q · filed 2022-08-08 | -$42.60M derived: sum of 3 quarters · filed 2023-02-27 | -$52.23M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$15.81M 10-Q · filed 2022-05-09 | -$26.21M derived: sum of 2 quarters · filed 2023-02-27 | -$35.84M derived: sum of 3 quarters · filed 2023-02-27 | -$42.66M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$20.03M derived: sum of 2 quarters · filed 2023-02-27 | -$26.84M derived: sum of 3 quarters · filed 2023-02-27 | -$32.17M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$9.63M 10-Q · filed 2021-11-08 | -$16.45M derived: sum of 2 quarters · filed 2021-11-08 | -$21.77M 10-Q · filed 2021-11-08 | -$27.13M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$6.82M 10-Q · filed 2021-08-09 | -$12.14M 10-Q · filed 2021-08-09 | -$17.50M derived: sum of 3 quarters · filed 2021-08-09 | -$21.78M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | -$5.33M 10-Q · filed 2021-05-10 | -$10.69M derived: sum of 2 quarters · filed 2021-05-10 | -$14.96M derived: sum of 3 quarters · filed 2021-05-10 | -$20.31M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | -$5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$9.64M derived: sum of 2 quarters · filed 2021-03-01 | -$14.98M derived: sum of 3 quarters · filed 2021-03-01 | -$19.08M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$4.28M 10-Q · filed 2020-11-09 | -$9.63M derived: sum of 2 quarters · filed 2020-11-09 | -$13.72M 10-Q · filed 2020-11-09 | -$17.43M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$5.35M 10-Q · filed 2020-08-07 | -$9.44M 10-Q · filed 2020-08-07 | -$13.15M derived: sum of 3 quarters · filed 2020-08-07 | -$15.90M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$4.10M 10-Q · filed 2020-05-04 | -$7.80M derived: sum of 2 quarters · filed 2020-05-04 | -$10.56M derived: sum of 3 quarters · filed 2020-05-04 | -$12.83M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | -$3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$6.46M derived: sum of 2 quarters · filed 2020-03-10 | -$8.74M derived: sum of 3 quarters · filed 2020-03-10 | -$10.89M 10-K · filed 2020-03-10 |
| 2018-09-30 | -$2.75M 10-Q · filed 2019-11-04 | -$5.03M derived: sum of 2 quarters · filed 2019-11-04 | -$7.18M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | -$2.28M 10-Q · filed 2019-08-05 | -$4.43M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | -$2.15M 10-Q · filed 2019-05-07 | |||
| 2017-09-30 | -$5.27M 10-Q · filed 2018-11-05 | -$6.03M derived: sum of 2 quarters · filed 2018-11-05 | -$6.53M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | -$759.00K 10-Q · filed 2018-08-06 | -$1.25M 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |